M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn Pharmaceutical Technologyargenx has entered into a definitive agreement to acquire Forte Biosciences for approximately $2.2bn in total equity value.Immunology & InflammationRead full story pharminent July 28, 2026 (Last updated: July 28, 2026) Pharmaceutical Technology argenx has entered into a definitive agreement to acquire Forte Biosciences for approximately $2.2bn in total equity value. Immunology & Inflammation Read full story Post navigation Previous: AstraZeneca Says Drug Pricing Is ‘Evolving’ in Response to Trump’s Most-Favored-Nation PolicyNext: GSK to quit Stevenage for new R&D site in Cambridge Related Stories M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026 M&A / Deals Sandoz targets industry patent void with $322m Henlius deal pharminent August 17, 2026 M&A / Deals PTC takes a chance on Sangamo’s Fabry disease gene therapy pharminent August 13, 2026
